Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P, Szer J, Weitz I, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro C, Nishimori H, Tan L, Hamdani M, Deschatelets P, Francois C, Grossi F, Ajayi T, Risitano A, Peffault de Latour R. Hillmen P, et al. Among authors: nishimori h. N Engl J Med. 2021 Mar 18;384(11):1028-1037. doi: 10.1056/NEJMoa2029073. N Engl J Med. 2021. PMID: 33730455 Clinical Trial.
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
de Latour RP, Szer J, Weitz IC, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro CM, Nishimori H, Ajayi T, Al-Adhami M, Deschatelets P, Francois C, Grossi F, Risitano AM, Hillmen P. de Latour RP, et al. Among authors: nishimori h. Lancet Haematol. 2022 Sep;9(9):e648-e659. doi: 10.1016/S2352-3026(22)00210-1. Lancet Haematol. 2022. PMID: 36055332 Clinical Trial.
Successful haematopoietic progenitor cell collection by plerixafor in combination with reduced dose granulocyte colony-stimulating factor for severe hypoxemia provoked by high-dose granulocyte colony-stimulating factor administration.
Kambara Y, Asada N, Kondo K, Sumii Y, Fujiwara Y, Seike K, Sando Y, Saeki K, Nishimori H, Fujii K, Fujii N, Matsuoka KI, Maeda Y. Kambara Y, et al. Among authors: nishimori h. Transfus Med. 2022 Dec;32(6):527-529. doi: 10.1111/tme.12916. Epub 2022 Sep 7. Transfus Med. 2022. PMID: 36071619 No abstract available.
Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation.
Seike K, Fujii N, Asano N, Ohkuma S, Hirata Y, Fujii K, Sando Y, Nakamura M, Naito K, Saeki K, Meguri Y, Asada N, Ennishi D, Nishimori H, Matsuoka KI, Tsubaki K, Otsuka F, Maeda Y. Seike K, et al. Among authors: nishimori h. Transfusion. 2020 Mar;60(3):473-478. doi: 10.1111/trf.15664. Epub 2020 Jan 22. Transfusion. 2020. PMID: 31970799
Progressive multifocal leukoencephalopathy after T-cell replete HLA-haploidentical transplantation with post-transplantation cyclophosphamide graft-versus-host disease prophylaxis.
Ikegawa S, Fujii N, Tadokoro K, Sato K, Iwamoto M, Matsuda M, Inomata T, Sugiura H, Asano T, Yoshida S, Nishimori H, Matsuoka KI, Maeda Y. Ikegawa S, et al. Among authors: nishimori h. Transpl Infect Dis. 2018 Apr;20(2):e12850. doi: 10.1111/tid.12850. Epub 2018 Mar 1. Transpl Infect Dis. 2018. PMID: 29359846
Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease.
Sugiyama H, Maeda Y, Nishimori H, Yamasuji Y, Matsuoka K, Fujii N, Kondo E, Shinagawa K, Tanaka T, Takeuchi K, Teshima T, Tanimoto M. Sugiyama H, et al. Among authors: nishimori h. Biol Blood Marrow Transplant. 2014 Feb;20(2):183-91. doi: 10.1016/j.bbmt.2013.11.018. Epub 2013 Dec 10. Biol Blood Marrow Transplant. 2014. PMID: 24333142 Free article.
259 results